Literature DB >> 32378089

Variation in Adequate Lymph Node Yield for Gastric, Lung, and Bladder Cancer: Attributable to the Surgeon, Pathologist, or Hospital?

Christopher T Aquina1, Matthew Truong2, Carla F Justiniano3, Roma Kaur3, Zhaomin Xu3, Francis P Boscoe4, Maria J Schymura4, Adan Z Becerra3.   

Abstract

BACKGROUND: The Commission on Cancer recently released quality-of-care measures regarding adequate lymphadenectomy for colon, gastric, lung, and bladder cancer. There is currently little information regarding variation in adequate lymph node yield (ALNY) for gastric, lung, and bladder cancer.
METHODS: The New York State Cancer Registry and Statewide Planning and Research Cooperative System were queried for stage I-III gastric, stage I-II lung, and stage II-III bladder cancer resections from 2004 to 2014. Hierarchical models assessed factors associated with ALNY (gastric ≥ 15; lung ≥ 10; bladder ≥ 2). Additionally, the proportions of variation attributable to surgeons, pathologists, and hospitals were estimated among Medicare patients.
RESULTS: Among 3716 gastric, 18,328 lung, and 1512 bladder cancer resections, there were low rates of ALNY (gastric = 53%, lung = 36%, bladder = 67%). When comparing 2004-2006 and 2012-2014, there was significant improvement in ALNY for gastric cancer (39% vs. 68%), but more modest improvement for lung (33% vs. 38%) and bladder (65% vs. 71%) cancer. Large provider-level variation existed for each organ system. After controlling for patient-level factors/variation, the majority of variation was attributable to hospitals (gastric: surgeon = 4%, pathologist = 2.8%, hospital = 40%; lung: surgeon = 13.8%, pathologist = 1.5%, hospital = 18.3%) for gastric and lung cancer. For bladder cancer, most of the variation was attributable to pathologists (surgeon = 3.3%, pathologist = 10.5%, hospital = 6.2%).
CONCLUSIONS: ALNY rates are low for gastric, lung, and bladder cancer, with only modest improvement over time for lung and bladder cancer. Given that the proportion of variation attributable to the surgeon, pathologist, and hospital is different for each organ system, future quality improvement initiatives should target the underlying causes, which vary by individual organ system.

Entities:  

Mesh:

Year:  2020        PMID: 32378089     DOI: 10.1245/s10434-020-08509-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

1.  Surgeon-, pathologist-, and hospital-level variation in suboptimal lymph node examination after colectomy: Compartmentalizing quality improvement strategies.

Authors:  Adan Z Becerra; Christopher T Aquina; Mariana Berho; Francis P Boscoe; Maria J Schymura; Katia Noyes; John R Monson; Fergal J Fleming
Journal:  Surgery       Date:  2017-01-11       Impact factor: 3.982

2.  Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage.

Authors:  Roderich E Schwarz; David D Smith
Journal:  Ann Surg Oncol       Date:  2006-11-09       Impact factor: 5.344

3.  A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data.

Authors:  Carl van Walraven; Peter C Austin; Alison Jennings; Hude Quan; Alan J Forster
Journal:  Med Care       Date:  2009-06       Impact factor: 2.983

4.  Variation in lymph node assessment after colon cancer resection: patient, surgeon, pathologist, or hospital?

Authors:  Hari Nathan; Andrew D Shore; Robert A Anders; Elizabeth C Wick; Susan L Gearhart; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2010-12-21       Impact factor: 3.452

5.  Inadequacy of lymph node staging in gastric cancer patients: a population-based study.

Authors:  Nancy N Baxter; Todd M Tuttle
Journal:  Ann Surg Oncol       Date:  2005-10-25       Impact factor: 5.344

6.  The role of the cancer center when using lymph node count as a quality measure for gastric cancer surgery.

Authors:  John W Morgan; Liang Ji; Garrett Friedman; Maheswari Senthil; Crickett Dyke; Sharon S Lum
Journal:  JAMA Surg       Date:  2015-01       Impact factor: 14.766

7.  Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer.

Authors:  Michelle S Ludwig; Michael Goodman; Daniel L Miller; Peter A S Johnstone
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

8.  Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.

Authors:  Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali
Journal:  Med Care       Date:  2005-11       Impact factor: 2.983

9.  Surgical factors influence bladder cancer outcomes: a cooperative group report.

Authors:  Harry W Herr; James R Faulkner; H Barton Grossman; Ronald B Natale; Ralph deVere White; Michael F Sarosdy; E David Crawford
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

10.  Variation in Hospital-Specific Rates of Suboptimal Lymphadenectomy and Survival in Colon Cancer: Evidence from the National Cancer Data Base.

Authors:  Adan Z Becerra; Mariana E Berho; Christian P Probst; Christopher T Aquina; Mohamedtaki A Tejani; Maynor G Gonzalez; Zhaomin Xu; Alex A Swanger; Katia Noyes; John R Monson; Fergal J Fleming
Journal:  Ann Surg Oncol       Date:  2016-09-09       Impact factor: 5.344

View more
  1 in total

1.  Assessment of Textbook Outcome After Surgery for Stage I/II Non-small Cell Lung Cancer.

Authors:  Sujay Kulshrestha; Wickii T Vigneswaran; Timothy M Pawlik; Marshall S Baker; Fred A Luchette; Wissam Raad; Zaid M Abdelsattar; Richard K Freeman; Tyler Grenda; James Lubawski
Journal:  Semin Thorac Cardiovasc Surg       Date:  2021-08-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.